These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 26795874)
61. Cognitive Efficacy (SIB) of 13.3 Versus 4.6 mg/24 h Rivastigmine Patch in Severe Alzheimer's Disease. Isaacson RS; Ferris S; Velting DM; Meng X Am J Alzheimers Dis Other Demen; 2016 May; 31(3):270-7. PubMed ID: 26371345 [TBL] [Abstract][Full Text] [Related]
62. Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson's disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled study. Vitek JL; Jain R; Chen L; Tröster AI; Schrock LE; House PA; Giroux ML; Hebb AO; Farris SM; Whiting DM; Leichliter TA; Ostrem JL; San Luciano M; Galifianakis N; Verhagen Metman L; Sani S; Karl JA; Siddiqui MS; Tatter SB; Ul Haq I; Machado AG; Gostkowski M; Tagliati M; Mamelak AN; Okun MS; Foote KD; Moguel-Cobos G; Ponce FA; Pahwa R; Nazzaro JM; Buetefisch CM; Gross RE; Luca CC; Jagid JR; Revuelta GJ; Takacs I; Pourfar MH; Mogilner AY; Duker AP; Mandybur GT; Rosenow JM; Cooper SE; Park MC; Khandhar SM; Sedrak M; Phibbs FT; Pilitsis JG; Uitti RJ; Starr PA Lancet Neurol; 2020 Jun; 19(6):491-501. PubMed ID: 32470421 [TBL] [Abstract][Full Text] [Related]
63. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Cree BAC; Cutter G; Wolinsky JS; Freedman MS; Comi G; Giovannoni G; Hartung HP; Arnold D; Kuhle J; Block V; Munschauer FE; Sedel F; Lublin FD; Lancet Neurol; 2020 Dec; 19(12):988-997. PubMed ID: 33222767 [TBL] [Abstract][Full Text] [Related]
64. Can cognitive enhancers reduce the risk of falls in older people with mild cognitive impairment? A protocol for a randomised controlled double blind trial. Montero-Odasso M; Wells JL; Borrie MJ; Speechley M BMC Neurol; 2009 Aug; 9():42. PubMed ID: 19674471 [TBL] [Abstract][Full Text] [Related]
65. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
66. Dynamic gait stability in people with mild to moderate Parkinson's disease. Ban R; Ahn J; Simpkins C; Lazarus J; Yang F Clin Biomech (Bristol, Avon); 2024 Aug; 118():106316. PubMed ID: 39059102 [TBL] [Abstract][Full Text] [Related]
68. Effects of augmenting cholinergic neurotransmission on balance in Parkinson's disease. Mancini M; Chung K; Zajack A; Martini DN; Ramsey K; Lapidus J; Horak FB; Nutt JG Parkinsonism Relat Disord; 2019 Dec; 69():40-47. PubMed ID: 31675664 [TBL] [Abstract][Full Text] [Related]
69. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. McKeith I; Del Ser T; Spano P; Emre M; Wesnes K; Anand R; Cicin-Sain A; Ferrara R; Spiegel R Lancet; 2000 Dec; 356(9247):2031-6. PubMed ID: 11145488 [TBL] [Abstract][Full Text] [Related]
70. Collapse in the elderly: rivastigmine-induced heart block and a literature review of the pharmacology of acetylcholinesterase inhibitors used in Alzheimer's disease. Alonge O; Iqbal FM; Cifonelli E BMJ Case Rep; 2018 Apr; 2018():. PubMed ID: 29666099 [TBL] [Abstract][Full Text] [Related]
71. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169 [TBL] [Abstract][Full Text] [Related]
72. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Farlow M; Potkin S; Koumaras B; Veach J; Mirski D Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489 [TBL] [Abstract][Full Text] [Related]
73. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Burn D; Emre M; McKeith I; De Deyn PP; Aarsland D; Hsu C; Lane R Mov Disord; 2006 Nov; 21(11):1899-907. PubMed ID: 16960863 [TBL] [Abstract][Full Text] [Related]
74. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial. Sandborn WJ; Panés J; Danese S; Sharafali Z; Hassanali A; Jacob-Moffatt R; Eden C; Daperno M; Valentine JF; Laharie D; Baía C; Atreya R; Panaccione R; Rydzewska G; Aguilar H; Vermeire S; Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):43-55. PubMed ID: 36240801 [TBL] [Abstract][Full Text] [Related]
75. Effects of dance on gait and dual-task gait in Parkinson's disease. Haputhanthirige NKH; Sullivan K; Moyle G; Brauer S; Jeffrey ER; Kerr G PLoS One; 2023; 18(1):e0280635. PubMed ID: 36693038 [TBL] [Abstract][Full Text] [Related]
76. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442 [TBL] [Abstract][Full Text] [Related]